Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation
Status:
Terminated
Trial end date:
2017-01-20
Target enrollment:
Participant gender:
Summary
This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of
intercalated combination of doublet chemotherapy of paclitaxel plus carboplatin and erlotinib
on patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR
mutation.